诺和锐30治疗2型糖尿病患者的初步观察

The First Step Observe of BIAsp30 in the Treatment of Type 2 Diabetes

目的:探讨诺和锐30对2型糖尿病的疗效和安全性。方法:采用自身前后对照,观察32例应用诺和灵30R或NPH胰岛素(NPH)或服用口服降糖药,NPH或二者联合治疗不理想的住院、门诊2型糖尿病患者,改为诺和锐30控制血糖以观察其疗效和完全性。结果:经治疗后患者空腹及餐后2h血糖,糖化血红蛋白均有明显下降,空腹胰岛素及C肽水平都有明显升高,无低血糖反应发生,平均随访3个月,糖化血红蛋白为(7.1±2.3)%,空腹血糖(8.5±2.7)mmol/L,餐后2h血糖为(11.5±3.6)mmol/L,空腹胰岛素(11.8±2.9)μIU/ml,空腹C肽(1.15±0.15)mg/ml。结论:2型糖尿病患者每日2次诺和锐30较诺和灵30R或NPH胰岛素治疗能更好地控制餐后血糖,减少低血糖的危险性。

Objective： To study the efficacy and safety of BIAsp30 in the treatment of type 2 diabetes,Methods：32 type 2 diabetic patients, who had bad control of serum glucose by the trealment of Novolin30R, NPH, combining with or without oral drugs, were treated with BIAsp30, and boththe efficacy and safety were observed. Results：After the treatment, the FBG, 2hPG, HbAlc of all patients were significantly decreased, the Fins and FCP were significantly increased. No hypoghycemia occured. 32 patients were followed up for an average of three months with mean HbAlc of （7.1 ± 2.3） %, fasting plasma glucose levels of （8.5 ± 2.7） mmoL/L, 2h OGTT plasma glucose levels of （ 11.5 ± 3.6 ） mmol/L, fasting insulin levels of （ 11.8 ± 2.9 ）μIU/ ml, fasting C - peptide levels of （1.15 ± 0.15）mg/ml. Conclusion： Type 2 diabetic patients who treated with BIAsp 30 twice a day can more effective and reduce the danger of hypoglycemia.